Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism

Chemistry and Biology

Volumn 11, Issue 11, 2004, Pages 1489-1493

  Lunn, Mitchell R ^a   Root, David E ^f   Martino, Allison M ^a   Flaherty, Stephen P ^a   Kelley, Brian P ^a   Coovert, Daniel D ^b   Burghes, Arthur H ^b   Thi Man, Nguyen ^c   Morris, Glenn E ^c   Zhou, Jianhua ^d   Androphy, Elliot J ^d   Sumner, Charlotte J ^e   Stockwell, Brent R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; INDOPROFEN; NERVE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RNA BINDING PROTEIN; SMN PROTEIN (SPINAL MUSCULAR ATROPHY);

ANIMAL; ARTICLE; BIOSYNTHESIS; DRUG SCREENING; ENZYMOLOGY; FEMALE; FIBROBLAST; GENETICS; HUMAN; MOUSE; PHYSIOLOGY; PREGNANCY; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBROBLASTS; HUMANS; INDOPROFEN; MICE; NERVE TISSUE PROTEINS; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA-BINDING PROTEINS; UP-REGULATION;

EID: 8844240017     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2004.08.024     Document Type: Article

References (41)

1. Melki J., Lefebvre S., Burglen L., Burlet P., Clermont O., Millasseau P., Reboullet S., Benichou B., Zeviani M., Le Paslier D., et al. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science. 264:1994;1474-1477
2. Melki J., Abdelhak S., Sheth P., Bachelot M.F., Burlet P., Marcadet A., Aicardi J., Barois A., Carriere J.P., Fardeau M., et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature. 344:1990;767-768
3. Pearn J. Classification of spinal muscular atrophies. Lancet. 1:1980;919-922
4. Lefebvre S., Burglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 80:1995;155-165
5. Coovert D.D., Le T.T., McAndrew P.E., Strasswimmer J., Crawford T.O., Mendell J.R., Coulson S.E., Androphy E.J., Prior T.W., Burghes A.H. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6:1997;1205-1214
6. Lefebvre S., Burlet P., Liu Q., Bertrandy S., Clermont O., Munnich A., Dreyfuss G., Melki J. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16:1997;265-269
7. McAndrew P.E., Parsons D.W., Simard L.R., Rochette C., Ray P.N., Mendell J.R., Prior T.W., Burghes A.H. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am. J. Hum. Genet. 60:1997;1411-1422
8. Stockwell B.R. Chemical genetic screening approaches to neurobiology. Neuron. 36:2002;559-562
9. Stockwell B.R. Chemical genetics. ligand-based discovery of gene function Nat. Rev. Genet. 1:2000;116-125
10. Stockwell B.R. Frontiers in chemical genetics. Trends Biotechnol. 18:2000;449-455
11. Kelley B.P., Lunn M.R., Root D.E., Flaherty S.P., Martino A.M., Stockwell B.R. A flexible data analysis tool for chemical genetic screens. Chem. Biol. 11:2004;1495-1503., this issue
12. Andreassi C., Jarecki J., Zhou J., Coovert D.D., Monani U.R., Chen X., Whitney M., Pollok B., Zhang M., Androphy E., et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet. 10:2001;2841-2849
13. Zhang M.L., Lorson C.L., Androphy E.J., Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA. potential therapy of SMA Gene Ther. 8:2001;1532-1538
14. Root D.E., Flaherty S.P., Kelley B.P., Stockwell B.R. Biological mechanism profiling using an annotated compound library. Chem. Biol. 10:2003;881-892
15. Goldaniga G.C., Montesanti L., Valzelli G. Tissue distribution of 14C-indoprofen in the rat. Arzneimittelforschung. 30:1980;1659-1661
16. Monani U.R., Sendtner M., Coovert D.D., Parsons D.W., Andreassi C., Le T.T., Jablonka S., Schrank B., Rossol W., Prior T.W., et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9:2000;333-339
17. Buhler D., Raker V., Luhrmann R., Fischer U. Essential role for the tudor domain of SMN in spliceosomal U snRNP assembly. implications for spinal muscular atrophy Hum. Mol. Genet. 8:1999;2351-2357
18. Carvalho T., Almeida F., Calapez A., Lafarga M., Berciano M.T., Carmo-Fonseca M. The spinal muscular atrophy disease gene product, SMN. a link between snRNP biogenesis and the Cajal (coiled) body J. Cell Biol. 147:1999;715-728
19. Fischer U., Liu Q., Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell. 90:1997;1023-1029
20. Lefebvre S., Burglen L., Frezal J., Munnich A., Melki J. The role of the SMN gene in proximal spinal muscular atrophy. Hum. Mol. Genet. 7:1998;1531-1536
21. Pellizzoni L., Charroux B., Dreyfuss G. SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc. Natl. Acad. Sci. USA. 96:1999;11167-11172
22. Kashima T., Manley J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 34:2003;460-463
23. Miyaso H., Okumura M., Kondo S., Higashide S., Miyajima H., Imaizumi K. An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA. J. Biol. Chem. 278:2003;15825-15831
24. Mourelatos Z., Abel L., Yong J., Kataoka N., Dreyfuss G. SMN interacts with a novel family of hnRNP and spliceosomal proteins. EMBO J. 20:2001;5443-5452
25. Pellizzoni L., Kataoka N., Charroux B., Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell. 95:1998;615-624
26. Skordis L.A., Dunckley M.G., Yue B., Eperon I.C., Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl. Acad. Sci. USA. 100:2003;4114-4119
27. Iwahashi H., Eguchi Y., Yasuhara N., Hanafusa T., Matsuzawa Y., Tsujimoto Y. Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. Nature. 390:1997;413-417
28. Schrank B., Gotz R., Gunnersen J.M., Ure J.M., Toyka K.V., Smith A.G., Sendtner M. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl. Acad. Sci. USA. 94:1997;9920-9925
29. Kerr D.A., Nery J.P., Traystman R.J., Chau B.N., Hardwick J.M. Survival motor neuron protein modulates neuron-specific apoptosis. Proc. Natl. Acad. Sci. USA. 97:2000;13312-13317
30. Young P.J., Day P.M., Zhou J., Androphy E.J., Morris G.E., Lorson C.L. A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy. J. Biol. Chem. 277:2002;2852-2859
31. Rossoll W., Jablonka S., Andreassi C., Kroning A.K., Karle K., Monani U.R., Sendtner M. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of β-actin mRNA in growth cones of motoneurons. J. Cell Biol. 163:2003;801-812
32. Zhang H.L., Pan F., Hong D., Shenoy S.M., Singer R.H., Bassell G.J. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J. Neurosci. 23:2003;6627-6637
33. Fan L., Simard L.R. Survival motor neuron (SMN) protein. role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development Hum. Mol. Genet. 11:2002;1605-1614
34. Case D.C. Jr., Ervin T.J., Boyd M.A., Bove L.G., Sonneborn H.L., Paul S.D. Phase II study of aclarubicin in acute myeloblastic leukemia. Am. J. Clin. Oncol. 10:1987;523-526
35. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA. 98:2001;9808-9813
36. Daniel P., Brazier M., Cerutti I., Pieri F., Tardivel I., Desmet G., Baillet J., Chany C. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin. Chim. Acta. 181:1989;255-263
37. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:2001;36734-36741
38. Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F.A., Raschke H., Blumcke I., Eyupoglu I.Y., Wirth B. Valproic acid increases the SMN2 protein level. a well-known drug as a potential therapy for spinal muscular atrophy Hum. Mol. Genet. 12:2003;2481-2489
39. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., Schussler K., Chen X., Jarecki J., Burghes A.H., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54:2003;647-654
40. Bruni G., Lavezzari M., Perbellini A., Battaglia A., Emanueli A. Adverse reactions to indoprofen. a survey based on a total of 6764 patients J. Int. Med. Res. 10:1982;306-324
41. Porro G.B., Corvi G., Fuccella L.M., Goldaniga G.C., Valzelli G. Gastro-intestinal blood loss during administration of indoprofen, aspirin and ibuprofen. J. Int. Med. Res. 5:1977;155-160